HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
- 1 June 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 15 (9) , F19-F27
- https://doi.org/10.1097/00002030-200106150-00001
Abstract
To evaluate whether controlled re-exposures to autologous HIV-1 could boost HIV-specific immunity and limit virus replication in patients with chronic HIV-1 infection. Subjects with at least 2 years virus suppression during antiretroviral therapy and a CD4 : CD8 ratio > 1 were randomly assigned to interrupt highly active antiretroviral treatment (HAART) three times (n = 12) or to continue their previous HAART (n = 14). In 10/12 interrupter patients a rebound of HIV-1 RNA was detected in all three structured treatment interruptions (STI). Plasma virus doubling time was shorter during the first STI than in the second and third STI, corresponding to an average 13% reduction in viral basic reproductive rate. However, the mean time before plasma viral load rose to > 50 copies/ml was significantly shorter in the second and third STI. The average frequency of HIV-specific CD8 T cells in the interrupter patients at the end of the third STI cycle was significantly higher compared with the baseline and the end of the first STI. A substantial increase in HIV-specific CD8 T cell frequencies was found in four interrupter patients, whereas there were no changes in all 14 non-interrupter individuals. A weak p24-specific T helper response developed in 5/12 interrupter patients compared with no response in non-interruptors, but these responses were transient and disappeared rapidly. The increase in the control of viral replication, and positive effects of STI on immune responses in this population should encourage the further development of HIV-specific immune-based therapeutic strategies.Keywords
This publication has 35 references indexed in Scilit:
- Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 InfectionJournal of Virology, 2001
- Enhancement of Human Immunodeficiency Virus Type 1–Specific CD4 and CD8 T Cell Responses in Chronically Infected Persons after Temporary Treatment InterruptionThe Journal of Infectious Diseases, 2000
- Strong Human Immunodeficiency Virus (HIV)–Specific CD4+T Cell Responses in a Cohort of Chronically Infected Patients Are Associated with Interruptions in Anti‐HIV ChemotherapyThe Journal of Infectious Diseases, 2000
- HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapyJournal of Clinical Investigation, 1999
- Functional T Cell Reconstitution and Human Immunodeficiency Virus–1–Specific Cell‐Mediated Immunity during Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 1999
- HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatmentAIDS, 1999
- Prolonged Suppression of Human Immunodeficiency Virus Type 1 (HIV?1) Viremia in Persons with Advanced Disease Results in Enhancement of CD4 T Cell Reactivity to Microbial Antigens but Not to HIV?1 AntigensThe Journal of Infectious Diseases, 1999
- Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 yearsAIDS, 1998
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995